Kevin Chin

As Chief Medical Officer for Marengo Therapeutics, Kevin brings more than 17 years of biopharma experience in oncology clinical development during which he has worked extensively on T cell directed therapies, particularly checkpoint inhibitors and more recently CAR-T cell therapy for solid tumors and hematologic malignances.

Kevin joins Marengo from 2seventybio, where he was the Head of Clinical Development for the Bluebirdbio spin-off company dedicated to the discovery of next generation CAR T-cell therapies for both hematologic malignancies and solid tumors. At 2seventybio, he was responsible for leading the clinical development organization as it launched Abecma, the first FDA-approved CAR T cell therapy for multiple myeloma, while also initiating first-in-human clinical trials of novel CAR T-cell therapies for B-cell NHL and pediatric AML.

Prior to 2seventybio, Kevin was at EMD Serono where he led the clinical development team for avelumab (anti-PD-L1), which earned global regulatory approvals for Merkel cell carcinoma, urothelial carcinoma, and renal cell carcinoma. Prior to EMD Serono, Kevin started his career in pharma at Bristol-Myers Squibb where he led global clinical development teams for both Ipilimumab (anti-CTLA4) and Nivolumab (anti-PD1).

Kevin completed his undergraduate studies at Princeton University and received his M.D. from the State University of New York – Downstate. He completed his Internal Medicine training and Hematology-Oncology fellowship at Tufts-New England Medical Center in Boston, MA. Kevin also earned a M.S. in Clinical Care Research at the Sackler School of Graduate Biomedical Sciences at Tufts University. Prior to joining the pharmaceutical industry, Kevin was an Assistant Professor of Medicine at Tufts University Medical School and Assistant Director of the Tufts Medical Center Evidence-based Practice Center.